Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label pharmacokinetic and safety study of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis patients aged 12 to less than 24 months
2023-503230-49-00Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Jul 2024; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2023-503230-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503230-49-00.